The Regenerating gene (REG) Ia protein, a trophic and/or anti-apoptotic factor, is important in the pathophysiology of gastrointestinal inflammation. Interleukin (IL)-22 is a recently identified cytokine that is suggested to have pivotal roles in inflammatory bowel diseases. We therefore investigated the involvement of the IL-22/REG Ia axis and examined the mechanism of regulation of REG Ia expression by IL-22 stimulation in ulcerative colitis (UC) mucosa. Expression of IL-22, IL-22 receptor 1 (IL-22R1), and REG Ia in UC mucosa was analyzed by real-time RT-PCR and immunohistochemistry. The effects of IL-22 on REG Ia protein expression were examined using a small-interfering RNA for STAT3, an MAPK inhibitor or a PI3K inhibitor. The element responsible for IL-22-induced REG Ia promoter activation was determined by a promoter deletion and electrophoretic mobility shift assay. The expression of IL-22 was enhanced in infiltrating inflammatory cells, and that of IL-22R1 and REG Ia was concurrently enhanced in the inflamed epithelium in UC mucosa. The levels of REG Ia and IL-22 mRNA expression were strongly correlated, and the distributions of REG Ia-and IL-22R1-positive epithelial cells were very similar. IL-22 simulation enhanced the expression of REG Ia protein through STAT3 tyrosine phosphorylation in colon cancer cells. The IL-22-responsive element was located between À142 and À134 in the REG Ia promoter region. REG Ia protein may have a pathophysiological role as a biological mediator for immune cell-derived IL-22 in the UC mucosa.
The Regenerating gene (REG), encoding a lectin-related protein, was originally isolated from rat regenerating pancreatic islet cells. 1 Thereafter, its human homologue REG Ia protein was suggested to be involved in the pathophysiology of gastrointestinal inflammation and its associated cancer. [2] [3] [4] [5] [6] Indeed, we previously reported that REG Ia protein behaves as a trophic and/or an anti-apoptotic factor in the development of colitis-or gastritis-associated cancer. 5, 6 To clarify the regulatory mechanism of REG Ia gene expression, we initially screened major cytokines and showed that interleukin (IL)-6 and IFN-g are possible stimulators of REG Ia gene expression under inflammatory conditions. 5, 6 However, the factors involved in ectopic expression of the REG Ia gene in the inflammatory gastrointestinal mucosa are still unclear.
IL-22 was recently identified as a cytokine produced by activated T cells. 7 Thereafter, accumulating data have indicated that not only IL-17-producing T (Th17) cells [8] [9] [10] [11] but also NK cells, 12, 13 dendritic cells, 14 and lymphoid tissue-inducer cells 15, 16 are responsible for IL-22 production. Conversely, the receptors for IL-22 are known to consist of two chains: IL-22 receptor 1 (IL-22R1) and IL-10R2. 17, 18 Interestingly, IL-10R2 is expressed ubiquitously in various organs, whereas IL-22R1 is expressed specifically in pancreas, skin, kidney, liver, and colon, 19, 20 and moreover its expression is detectable in epithelial cells but not in immune cells in these organs. 20 Thus, IL-22 may have pivotal roles in signaling from the immune system to epithelial cells under inflammatory conditions. Recently, it was suggested that IL-22 has a central role in the pathophysiology of inflammatory bowel disease. 21, 22 REG Ia, on the other hand, has been isolated in several microarray studies as a distinctly upregulated gene in the colonic epithelium in ulcerative colitis (UC). 23, 24 Interestingly, Zheng et al 14 have recently reported that IL-22 mediates host defense against bacterial pathogens by inducing Reg family proteins in mice. In this study, therefore, we attempted to clarify whether the IL-22/REG Ia axis is involved in the pathophysiology of UC and examined the regulatory mechanism of REG Ia expression by IL-22 stimulation in UC mucosa. Real-Time RT-PCR Total RNA was isolated from the biopsy samples with Trizol reagent (Gibco-BRL, Rockville, MD, USA). Total RNA (4 mg) was reverse-transcribed using oligo-dT primer (Applied Biosystems, Branchburg, NJ, USA) and real-time RT-PCR was performed with the ABI PRISM 7000 Sequence Detection System (Applied Biosystems) as previously reported. 27 The set of primers for IL-22, IL-22R1, REG Ia, and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) were prepared as shown in Table 1 . Real-time RT-PCR assays were carried out with 100 ng RNA equivalent cDNA, SYBR Green Master Mix (Applied Biosystems), and 500 nmol/l genespecific primers. The PCR cycling conditions were 501C for 2 min, 951C for 10 min, followed by 40 cycles at 951C for 15 s, and 601C for 60 s. The intensity of the fluorescent dye was determined, and the expression levels of IL-22, IL-22R1, and REG Ia mRNA were normalized to GAPDH mRNA expression levels. Immunohistochemical double staining was performed in UC tissues as previously reported. 6 In brief, the sections were incubated with goat anti-IL-22 antibody (1:50), mouse anti-CD3 antibody (1:200; Novocastra, Newcastle, UK), rabbit anti-IL-17 antibody (1:20; Santa Cruz Biotechnology), mouse anti-CD56 antibody (1:100; Novocastra) or mouse antiCD11c antibody (1:50; Novocastra) for 60 min at room temperature. Then, the sections were incubated with fluorescein isothiocyanate-conjugated anti-goat immunoglobulin (1:50; Dako, Glostrup, Denmark) and tetramethylrhodamine isothiocyanate-conjugated anti-mouse immunoglobulin (1:50; Dako) or tetramethylrhodamine isothiocyanate-conjugated anti-rabbit immunoglobulin (1:50; Dako) for 30 min at room temperature. After washing in phosphate-buffered saline, the sections were observed by confocal laser microscopy (DP70; Olympus, Tokyo, Japan).
MATERIALS AND METHODS Tissue Specimens and Histological Examination

Immunohistochemical Staining
Cell Culture and Reagents
Human colon cancer cell lines SW403 and LoVo cells were cultured in RPMI 1640 medium (Invitrogen, Grand Island, NY, USA) with 10% fetal bovine serum (Sigma, St Louis, MO, USA) in a humidified incubator at 371C with an atmosphere of 5% CO 2 . Human IL-22 was purchased from R&D Systems (Minneapolis, MN, USA). MEK inhibitor PD98059 and PI3K-Akt inhibitor wortmannin were from Sigma. Anti-STAT3, anti-phospho-specific STAT3 (Tyr705), anti-Akt, anti-phospho-specific Akt (Ser473), anti-ERK, and anti-phospho-specific ERK antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-b-actin antibody was purchased from Sigma.
Western Blot Analysis
After treatment with or without reagents, cells were lysed in protein extraction buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 50 mM NaF, and 1 Â proteinase inhibitor (Complete Mini; Roche, Mannheim, Germany). Protein extract (30 mg) was fractionated by SDS-polyacrylamide gel electrophoresis and transferred to a polyvinylidene difluoride membrane. The membrane was incubated with a primary antibody and then with a peroxidase-conjugated secondary antibody. Proteins were detected using an enhanced chemiluminescence system (Amersham Biosciences, Buckinghamshire, UK).
RNA Interference
Small-interfering RNA for human STAT3 (STAT3-siRNA) was obtained from Qiagen (Hilden, Germany). Cells were seeded in 6 cm dish (Iwaki, Funabashi, Japan) and maintained for 24 h. Then, the cells were transfected with 25 nM STAT3-siRNA or non-silencing siRNA (as a control) using 
Promoter Assay
The fragment of the human REG Ia promoter from À1195 to þ 78 (À1195/ þ 78) was cloned and inserted in the pGL3-Basic vector (Promega, Madison, WI, USA) as previously reported. 5 In brief, to obtain the deletion constructs, REG Ia promoter fragments of À811/ þ 78, À566/ þ 78, À339/ þ 78, À211/ þ 78, À153/ þ 78, À131/ þ 78, and À55/ þ 78 were also cloned and inserted in the pGL3-Basic vector. Mutant plasmids were constructed to monitor the function of the sequences in the REG Ia promoter corresponding to the potential IL-22 response element. Plasmids À153M1 and À153M2 were generated, in which the IL-22 response element was modified. The following oligonucleotides were used: for À153M1, 5 0 -CTCCCAGTGTGTGCCATACGAAGG-3 0 ; for À153M2, 5 0 -CTCCCAGTGCAGTAGGAAAAGG-3 0 , the underlined sequences corresponding to modified regions. The oligonucleotide used for the opposite orientation was 5 0 -CCCGAAGATTTTAGATCTAGAGTGC-3 0 in all cases. After cloning and confirmation of the nucleotides by sequencing, the construct was named hREG Ia-Luc. Luciferase assays were performed using the Dual Luciferase Reporter Assay system (Promega). Both firefly and Renilla luciferase activities were assayed by a luminometer (Lumat LB 9507; Berthold, Germany). The results obtained were normalized for Renilla luciferase activity and expressed relative to the activity of the untreated cell group.
Electrophoretic Mobility Shift Assay DNA probes for EMSA were synthesized as oligonucleotides. The sequences of the individual oligonucleotides in the sense orientation were as follows: probe WT, 5
0 -AGTGTGTGCCG GGAAAAGG-3 0 corresponding to nucleotides À148 to À130 of the REG Ia promoter gene; probe M1, 5
0 -AGTGTGTGCC ATACGAAGG-3 0 ; probe M2, 5 0 -AGTGTGCAGTAGGAAAA GG-3 0 . SW403 cells were pretreated with or without STAT3-siRNA or 20 mM PD 98059, followed by stimulation with IL-22 (10 ng/ml) for 30 min, and nuclear protein was extracted as previously described. 28 EMSA was carried out with a Gel Shift Assay System (Promega) in accordance with the manufacturer's recommendation. Briefly, the probes were generated by 5 0 -end labeling with [g-32 P]ATP (Amersham Biosciences) and T4 polynucleotide kinase (Promega). The nuclear protein (10 mg) was preincubated in a final volume of 9 ml of buffer containing 10 mM Tris-HCl (pH 7.5), 1 mM MgCl 2 , 50 mM NaCl, 0.5 mM EDTA, 4% glycerol, 0.5 mM DTT, and 0.5 mg of poly(dl-dC) for 10 min at room temperature. Then, the 32 P-labeled probe was added to the mixture, followed by incubation for 20 min at room temperature. For the supershift assay, 2 mg of antibody was added to the preincubation mixture, and additionally incubated for 15 min. The protein-DNA complexes were electrophoresed on a 6% acrylamide gel, and the gels were dried before autoradiography.
Statistical Analysis
All values for relative luciferase activity and real-time RT-PCR were expressed as the mean ± s.e.m. These data were analyzed using an unpaired two-tailed t-test. The relationship between REG Ia, IL-22, and IL-22R1 mRNA levels was assessed by linear regression analysis. P-values of less than 0.05 were considered to indicate statistical significance.
RESULTS
Expression of IL-22, IL-22R1, and REG Ia mRNA is Enhanced in UC Mucosa
To investigate whether the IL-22/REG Ia axis is involved in the pathophysiology of inflammatory bowel disease, we examined the expression of IL-22, IL-22R1, and REG Ia mRNA in UC tissues by real-time RT-PCR analysis. Both IL-22 and REG Ia expression were significantly greater in UC tissues than in normal colonic tissue (Figure 1) . Moreover, the level of IL-22R1 mRNA was significantly greater in UC tissue than in normal colonic tissue. We then analyzed the relationship between IL-22, IL-22R1, and REG Ia expression in UC tissues. The expression of REG Ia in UC tissues was significantly correlated with that of IL-22 and IL-22R1 (Figure 2a ). The expression of IL-22R1 in UC tissues was also correlated with that of IL-22.
Localization of IL-22, IL-22R1, and REG Ia Protein Expression in Normal Colonic and UC Mucosa
In normal colonic mucosa, immunoreactivity for IL-22 was hardly detected even in lymphocytes ( Figure 3a) . As shown in Figure 3b and c, IL-22R1 and REG Ia were coexpressed in a few epithelial cells in the basal portion of crypts (arrows). In UC mucosa, the numbers of IL-22-positive lymphocytes and IL-22R1-positive crypt cells were increased (Figure 3d and e) . Both the number of REG Ia-positive crypt cells and the signal intensity in each cell were also increased in UC mucosa (Figure 3f ).
To clarify which types of cells produce IL-22 in UC mucosa, we moreover carried out double immunostainings for IL-22 and several cell markers. CD3-positive T cells were observed throughout lamina propria, whereas IL-22-positive 
IL-22 Enhances REG Ia Promoter Activity and Protein Expression in Colon Cancer Cells
The effect of IL-22 stimulation on REG Ia promoter activity was examined in two colon cancer cell lines by luciferase reporter assay. In both SW403 and LoVo cells, REG Ia promoter activity was enhanced by IL-22 stimulation in a dose-dependent manner (0-100 ng/ml) (Figure 5a and b) . Nuclei were stained with DAPI (blue signal) using ProLong Gold and SlowFade Reagents (Invitrogen). E, epithelial cell structure.
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Western blot analysis also showed that the expression of REG Ia protein was enhanced in SW403 and LoVo cells at 12 and 24 h after IL-22 stimulation (Figure 5c and d).
IL-22 Induces Phosphorylation of ERK, STAT3, and AKT in Colon Cancer Cells
We next examined the activation of three major types of intracellular signaling possibly linked to IL-22 stimulation in colon cancer cells. IL-22 strongly activated STAT3 phosphorylation and moderately activated ERK phosphorylation from 5 min after stimulation in both SW403 and LoVo cells. IL-22 stimulation induced Akt phosphorylation in SW403 cells, but did not affect the phosphorylation of Akt in LoVo cells ( Figure 6 ).
IL-22 Enhances REG Ia Protein Expression in Colon Cancer Cells by a STAT3-Dependent Mechanism
Using an siRNA system for STAT3, we examined the contribution of STAT3 signaling to IL-22-induced REG Ia expression in colon cancer cells. As shown in Figure 7a ) were cultured in 6 cm dishes for 24 h. After the cells had been treated with IL-22 (10 ng/ml) for 12 and 24 h, extracted protein was analyzed using western blotting. 
MAPK Signaling is Partially Responsible for IL-22-Induced REG Ia Protein Expression in Colon Cancer Cells
We examined whether MAPK or PI3K-Akt signaling is involved in IL-22-induced REG Ia expression in colon cancer cells. The increased level of phospho-specific ERK in IL-22-treated cells was inhibited by concomitant administration of the MEK inhibitor PD 98059 (Figure 8a and b) . In addition, the increased level of phospho-specific Akt in SW403 cells treated with IL-22 was decreased by treatment with the PI3K inhibitor wortmannin (Figure 8a ). In the case of LoVo cells, the basic level of phospho-specific Akt was high, and IL-22 stimulation had no additional effect on the increase in the phospho-specific Akt level, suggesting that Akt may be constitutively activated in LoVo cells. However, the treatment with wortmannin (500 nM) abolished Akt activation in LoVo cells. We then examined whether inhibition of MAPK signaling or PI3K-Akt signaling affected REG Ia promoter activity and protein expression. Treatment with PD 98059 partially attenuated IL-22-induced REG Ia promoter activity, whereas treatment with wortmannin did not affect REG Ia promoter activity in both colon cancer cells (Figure 8c and d) . Consistent with these data, treatment with PD 98059 partially decreased IL-22-induced REG Ia protein expression in colon cancer cells. However, wortmannin did not affect REG Ia protein expression in either SW403 or LoVo cells (Figure 8e and f). These findings suggest that IL-22 stimulation can activate both MAPK and Akt signaling in those cells, and moreover that MAPK but not Akt signaling is in part linked to REG Ia expression in colon cancer cells.
Determination of the Element Responsive to IL-22-Induced REG Ia Promoter Activation in Colon Cancer Cells
The element responsive to IL-22-induced REG Ia promoter activation was determined in a series of promoter deletion assays. When deletion of the 5 0 REG Ia promoter gene was extended from position À1195 to À153, a significant increase of luciferase activity was sustained. However, the luciferase activity returned to the control level when the promoter region was additionally deleted up to À131 (Figure 9a ). These findings suggest that the promoter region between À153 and À131 is critical for REG Ia promoter activation by IL-22 stimulation. To identify the precise consensus sequences for IL-22-induced REG Ia promoter activation, we used mutant constructs ( Figure 9b ). As shown in Figure 9c , neither À153M1 nor À153M2 responded to IL-22 stimulation, suggesting that the element located between position À142 and À134 (TGCCGGGAA) is responsible for IL-22-induced REG Ia promoter activation. The binding of the nuclear extract to candidate nucleotides for the IL-22-responsive element was examined by EMSA. IL-22 enhanced the binding of nuclear extracts to the probe, and this enhanced activity was reduced by inhibition of STAT3 signaling with the siRNA system. However, inhibition of MAPK signaling did not affect the binding activity (Figure 9d) . Moreover, disruption of the responsive element resulted in complete loss of the binding activity (Figure 9e) . Finally, supershift analysis clearly revealed a supershifted band when the responsive elementbinding nuclear factors were treated with anti-STAT3 antibody, suggesting that IL-22-induced STAT3 proteins bind to the responsive element in the REG Ia promoter region (Figure 9f) .
DISCUSSION
Although the pathogenesis of UC is still unclear, accumulating evidence suggests that active cross talk mediated by cytokines between immune and nonimmune cells is importantly involved in the amelioration and/or exacerbation of inflammation in UC mucosa. 29, 30 Interestingly, IL-22 is thought to be produced by immune cells such as Th17, NK, 31, 32 anti-bacterial peptides (b-defensin, calgranulins), 33, 34 and mucin (MUC1, -3, -10, and -13). 35, 36 In this study, we examined whether IL-22 stimulation is responsible for REG Ia overexpression in the colonic epithelium in UC mucosa, because in several gene tip analyses REG Ia has been proven to be a distinctly upregulated gene in the colonic epithelium of patients with UC. 23, 24 Moreover, we found using microarray analysis that REG Ia is also a novel upregulated gene in a colon cancer cell line stimulated with IL-22 (data not shown). First, the expression of REG Ia was strongly correlated with that of IL-22 in UC mucosal tissues. Second, the distributions of REG Ia-and IL-22R1-positive epithelial cells were similar, and the infiltration of IL-22-positive inflammatory cells was increased around such colonic epithelial cells. Third, in vitro studies revealed that IL-22 stimulation indeed enhances REG Ia expression in colon cancer cell lines. Conversely, it was interesting that REG Ia and IL-22R1 were coexpressed in a few crypt cells in normal colonic glands, although the biological significance of this was unclear. Together, it appears reasonable to speculate that IL-22 stimulation is responsible for REG Ia overexpression in the colonic epithelium of UC mucosa.
In this study, we also examined the mechanism by which IL-22 signaling is linked to the enhancement of REG Ia expression in colonic epithelial cells. A series of in vitro studies clearly showed that IL-22 stimulation enhances REG Ia expression through STAT3 tyrosine phosphorylation and that the STAT3-binding site lies between À142 and À134 in the REG Ia promoter region. Alternatively, we also found that ERK signaling is in part associated with IL-22-induced REG Ia expression. Interestingly, it has been reported that ERK activation promotes STAT3 serine phosphorylation and upregulates its target protein expression in a few cell lines. 37, 38 Therefore, we stimulated a colon cancer cell line with IL-22, and subsequently found that IL-22 stimulation is possible to enhance REG Ia expression by ERK-dependent STAT3 serine phosphorylation in such cells (Supplementary Figure 1) . Although the whole network of IL-22-induced intracellular signaling leading to REG Ia expression still remains to be elucidated, it is certain that STAT3 signaling is crucial for IL-22-induced REG Ia expression (Supplementary Figure 2) .
What pathophysiological roles, then, does IL-22 has in the UC mucosa? At present, although we have no obvious answers in patients with UC, but a colitis-model of UC has recently revealed that IL-22 ameliorates intestinal inflammation by enhancing the production of membranebound mucins (MUC-1, -3, and -13) from colonic epithelium. 35 Zenewicz et al 12 have also reported recently that IL-22 derived from T and NK cells protects mice from inflammatory bowel disease. Moreover, several studies have emphasized that IL-22 mediates host defense against bacterial pathogens 14, 39 and furthermore promotes wound healing by exerting cell proliferative and/or anti-apoptotic effects. 33, 40 Thus, IL-22 may be involved in the protection of colonic mucosa from inflammation, or in recovery from colonic mucosal injury. Interestingly, Zheng et al 14 have very recently reported that Reg family proteins mediate the antibacterial effect of IL-22 in murine experimental colitis. Conversely, along with others, we have suggested that REG family proteins are importantly involved in the regeneration of gastrointestinal mucosa by exerting mitogenic and/or antiapoptotic effects. 4, 6, 27, 41 Accordingly, together with our present data, it is tempting to speculate that REG family proteins are pivotal targets for IL-22 in protecting the colonic mucosa from inflammation-associated injury, although further studies will be needed to test this hypothesis.
In summary, we have shown that the expression of IL-22 is enhanced in infiltrating inflammatory cells and that expression of IL-22R1 and REG Ia is concurrently enhanced in the inflamed epithelium in UC mucosa. In addition, we have clarified that IL-22 stimulation enhances REG Ia expression by activating its gene promoter through the STAT3 pathway in vitro. Taken together, these data suggest that REG Ia protein acts as a biological mediator for immune cell-derived IL-22 in the pathogenesis of UC.
